Bristol-Myers Squibb Compnay

Sanofi-Aventis

Sanofi-Synthelabo

Mark D Lindrud

Chenkou Wei

Olivier Monnier

San Kiang

Bruno Franc

Christian Hoff

Janak Singh

Soojin Kim

Madhusudhan Pudipeddi

The invention relates to a novel crystalline form of irbesartan to pharmaceutical compositions containing it, to processes for preparing it, and to a method for treating cardiovascular diseases utilizing it.

Form of irbesartan, processes for obtaining the said and pharmaceutical compositions containing it

The invention relates to a novel crystalline form of irbesartan, to pharmaceutical compositions containing it, to processes for preparing it, and to a method for treating cardiovascular diseases utilizing it.

Form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same

A novel apparatus and process for crystallizing submicron-sized crystals of a pharmaceutical composition. The submicron-sized crystals, which have an average size of less than 1 micron, provide high surface area end product crystals with greatly improved stability and purity, and which afford crystals having improved bioavailability, higher dissolution, decreased decomposition rate and longer shelf-life.

Sonic impinging jet crystallization apparatus and process

The present invention provides the crystalline bisulfate salt of the formula ##STR1## which is found to have unexpectedly high solubility/dissolution rate and oral bioavailability relative to the free base form of this azapeptide HIV protease inhibitor compound.

Bisulfate salt of HIV protease inhibitor

Growing community of inventors

Basking Ridge, NJ, United States of America

Mark D Lindrud